John Boyce
In 2013, John was named one of the top 15 Technology Luminaries in Massachusetts by the Boston Business Journal and Mass High Technology.
John is both a genomics and proteomics serial entrepreneur with seven successful exits and a venture capitalist focusing on therapeutics, tools, and diagnostics, specializing in building and positioning companies for either acquisition or an IPO. He has formed two successful venture capital firms – Tiger Gene, seeded by Tiger Management, and 28 Capital, a rebrand and expansion of Tiger Gene.
He has successfully raised over $800MM in funding and amassed >$1.8bn through exits. Before co-founding TigerGene Capital and John’s last exit as a serial entrepreneur, John was President and CEO of Exosome Diagnostics, which he led to a successful $575MM acquisition by Bio-Techne. John is also a Fellow at Harvard University, where he teaches ‘Entrepreneurship and Innovation.’
